Oncology Penny Stocks

US-listed oncology penny stocks priced $0.50 to $5, ranked by today's percentage change. Cancer-focused drug developers, immuno-oncology, radioligand therapy, ADC platforms, CAR-T, and oncology-diagnostics plays. Updated intraday.

Data as of 10/13/2026 6:35:58 AM · Intraday prices · 100 penny stocks in theme
#SymbolCompanySectorPriceDay ChgVolume
1PCSAProcessa Pharmaceuticals, Inc. CommonHealthcare$1.8690+24.01%423K
2BOLTBolt Biotherapeutics, Inc. Common StockHealthcare$4.2750+9.98%28K
3PDSBPDS Biotechnology Corporation Common Stock$1.4820+9.78%14.7M
4BGMSBio Green Med Solution, Inc. Common StockHealthcare$0.9640+7.53%182K
5ADCTADC Therapeutics SAHealthcare$1.8550+6.94%1.5M
6XBIOXenetic Biosciences, Inc.Healthcare$2.1350+5.40%8K
7BYSIBeyondSpring Inc. Ordinary SharesHealthcare$0.6060+4.11%37K
8RLMDRelmada Therapeutics, Inc. Common StockHealthcare$3.5330+3.69%1.3M
9MDXHMDxHealth SA Ordinary SharesHealthcare$0.5970+3.44%292K
10MRKRMarker Therapeutics, Inc. Common StockHealthcare$1.0010+3.44%103K
11TVRDTvardi Therapeutics, Inc. Common StockHealthcare$1.0510+2.91%242K
12APVOAptevo Therapeutics IncHealthcare$1.7550+2.79%241K
13KAPAKairos Pharma, Ltd.Healthcare$0.8090+2.68%240K
14ACTUActuate Therapeutics, Inc. Common stockHealthcare$0.6660+2.41%268K
15TLSITriSalus Life Sciences, Inc. Common StockHealthcare$4.1450+2.09%60K
16CSBRChampions Oncology, Inc.Healthcare$4.9800+1.76%11K
17CRISCuris IncHealthcare$0.6300+1.65%127K
18HOWLWerewolf Therapeutics, Inc. Common StockHealthcare$0.9850+1.61%809K
19ALXOALX Oncology Holdings Inc. Common StockHealthcare$1.2700+1.20%805K
20TARAProtara Therapeutics, Inc. Common Stock$2.7800+0.73%1.0M
21OKUROnKure Therapeutics, Inc. Class A Common StockHealthcare$2.4200+0.41%133K
22GERNGeron CorpHealthcare$1.22500.00%3.4M
23ZCMDZhongchao Inc. Class A Ordinary SharesHealthcare$1.41500.00%111K
24RNAZTransCode Therapeutics, Inc. Common StockHealthcare$1.64500.00%31K
25ERNAErnexa Therapeutics Inc. Common StockHealthcare$2.26500.00%28K
26BCTXLBriaCell Therapeutics Corp. Warrant expiring 2031$1.02400.00%8K
27SRTSSensus Healthcare, IncHealthcare$2.94000.00%6K
28TPSTTempest Therapeutics, Inc. Common StockHealthcare$0.7610-0.01%160K
29NUVBNuvation Bio Inc.Healthcare$4.9060-0.20%2.6M
30XBITXBiotech IncHealthcare$2.2650-0.22%42K
31GNLXGenelux Corporation Common StockHealthcare$2.5400-0.39%71K
32BOLDBoundless Bio, Inc. Common StockHealthcare$2.5350-0.40%58K
33GDTCCytoMed Therapeutics Limited Ordinary SharesHealthcare$0.8350-0.45%51K
34ACRVAcrivon Therapeutics, Inc. Common StockHealthcare$1.8870-0.52%137K
35MGNXMacroGenics, Inc.Healthcare$3.7250-0.53%232K
36GNPXGenprex, Inc. Common StockHealthcare$2.7010-0.74%265K
37ELTXElicio Therapeutics, Inc. Common StockHealthcare$1.8800-1.06%148K
38CTORCitius Oncology, Inc. Common StockHealthcare$0.7990-1.18%66K
39PYXSPyxis Oncology, Inc. Common StockHealthcare$2.0100-1.23%464K
40NTHINeOnc Technologies Holdings, Inc. Common StockHealthcare$2.7980-1.26%96K
41CLRBCellectar Biosciences INC NEWHealthcare$1.5000-1.38%165K
42BBOTBridgeBio Oncology Therapeutics, Inc. Common StockHealthcare$3.2500-1.66%190K
43ICCMIceCure Medical Ltd. Ordinary SharesHealthcare$1.0700-1.82%78K
44FATEFate Therapeutics, Inc.Healthcare$2.1300-1.83%546K
45IMNNImunon, Inc. Common StockHealthcare$1.0620-1.85%42K
46IMRXImmuneering Corporation Class A Common StockHealthcare$3.8400-1.90%480K
47APREAprea Therapeutics, Inc. Common stockHealthcare$0.5890-1.94%106K
48INDPIndaptus Therapeutics, Inc. Common StockHealthcare$2.4350-1.99%357K
49ENGNenGene Therapeutics Inc. Common StockHealthcare$1.7200-2.02%453K
50IPSCCentury Therapeutics, Inc. Common StockHealthcare$1.3670-2.04%346K

Trading Sub-$5 Oncology

Oncology is the most catalyst-rich corner of biotech. Cancer trials produce frequent readouts, FDA decisions are highly visible, and a single Phase 1/2 hit can rerate a company 500-1,500%. The flip side: clinical holds and failed primary endpoints can wipe out 60-90% in a session. This is binary-event trading at its purest.

  • ASCO & ESMO conferences: major oncology conferences (May, September, June) are catalyst-dense windows. Abstracts publish 3-4 weeks before the meeting.
  • PDUFA dates: FDA action dates for cancer drugs are scheduled events — visible on FDA.gov.
  • Trial readout calendar: companies pre-announce expected readout windows; the windows themselves are the trade setup.
  • Indication breadth: companies with multiple cancer indications are more durable than single-asset plays. Platform technologies (ADCs, radioligands, bispecifics) command premiums.
  • Survival endpoints: overall survival (OS) is the gold standard; surrogate endpoints (PFS, response rate) are weaker. Pay attention to which the trial used.
  • Partnership leverage: a Big Pharma licensing deal can revalue a sub-$5 oncology company overnight.
  • Dilution constant: oncology development is expensive. Most sub-$5 names raise capital every 6-18 months — see our dilution explainer.
  • Halt risk on readout days: volatility halts (LUDP) are routine on trial-data days — see our halt guide.

See also: biotech penny stocks (broader), genomics penny stocks, penny stocks under $1.

Market themes and sectors — the full-market view, all price ranges.